Go Deep
Gland Pharma Limited
Gland Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 21,226 | 42.4 | 4.76 | 0.03 | 2,989.70 |
| Oct 2026 | 21,546 | 42.0 | 4.58 | 0.03 | 2,874.40 |
| Oct 2026 | 20,718 | 44.7 | 4.88 | 0.03 | 3,061.80 |
Gland Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 18,002,710,000.0 | 17,427,900,000.0 | 16,953,630,000.0 | 15,056,220,000.0 |
| Net Profit | 3,169,590,000.0 | 3,666,750,000.0 | 2,614,750,000.0 | 2,154,820,000.0 |
| EPS | 19.2 | 22.3 | 15.9 | 13.1 |
Gland Pharma Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 64,029,020,000.0 | 55,836,260,000.0 | 56,417,320,000.0 | 35,918,590,000.0 |
| Net Profit | 10,273,160,000.0 | 6,985,260,000.0 | 7,724,600,000.0 | 7,810,430,000.0 |
| EPS | 62.4 | 42.4 | 46.9 | 47.4 |
Gland Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 125,108,480,000.0 | 112,249,200,000.0 | 106,612,460,000.0 | 87,775,350,000.0 | — |
| Total Liabilities | 21,528,980,000.0 | 20,741,790,000.0 | 19,374,030,000.0 | 8,188,130,000.0 | — |
| Total Equity | 103,579,500,000.0 | 91,507,410,000.0 | 87,238,430,000.0 | 79,587,220,000.0 | — |
Owes vs Owns
Gland Pharma Limited owed ₹0.17 for every ₹1 it owned in Mar 2026, up from ₹0.09 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.18× | 0.18× | 0.09× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Gland Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 26.8%Receivables 15.1%Inventory 13.9%Fixed assets (tangible) 35.8%Intangible assets 3.2%Other assets 5.1%
How it's funded — Mar 2026
Short-term debt 1.4%Long-term debt 0.6%Payables 6.7%Other liabilities 8.6%Shareholders' equity 82.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 3,359.1 | 2,952.2 | 1,938.8 | 3,762.8 |
| Receivables | 1,891.4 | 1,516.5 | 1,558.7 | 871.4 |
| Inventory | 1,743.9 | 1,685.2 | 1,655.2 | 1,945.3 |
| Fixed assets (tangible) | 4,473.6 | 3,975.0 | 3,871.0 | 1,799.1 |
| Intangible assets | 402.5 | 353.9 | 354.5 | 11.7 |
| Long-term investments | 0.0 | 0.0 | 654.5 | 0.0 |
| Other assets | 640.4 | 742.1 | 628.6 | 387.3 |
| Liabilities & equity | ||||
| Short-term debt | 173.4 | 191.6 | 213.2 | 0.6 |
| Long-term debt | 69.9 | 77.7 | 106.5 | 3.3 |
| Payables | 833.9 | 820.4 | 767.7 | 587.4 |
| Other liabilities | 1,075.7 | 984.6 | 849.9 | 227.6 |
| Shareholders' equity | 10,358.0 | 9,150.7 | 8,723.8 | 7,958.7 |
| Net tangible assets | 9,955.5 | 8,796.8 | 8,369.4 | 7,947.1 |
Gland Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 10,313,870,000.0 | 9,147,300,000.0 | 9,967,970,000.0 | 3,639,680,000.0 | — |
| Investing Activities | 1,377,280,000.0 | 17,047,360,000.0 | -17,569,110,000.0 | 12,081,880,000.0 | — |
| Financing Activities | -4,169,710,000.0 | -4,334,760,000.0 | -7,994,160,000.0 | 149,190,000.0 | — |